Categories Earnings, Health Care

GW Pharma (GWPH) Q4 loss narrows on strong sales; set to launch Epidiolex in Europe

GW Pharmaceuticals (NASDAQ: GWPH) reported a narrower net loss for the fourth quarter of 2019 as net sales rose sharply, with strong contributions from the company’s flagship product Epidiolex. The top-line also beat the market’s prediction. The company said it is on track to launch Eiodiolex in Europe in the first quarter.

GW Pharmaceuticals cash details

Net loss narrowed to $24.95 million or $0.07 per share in the fourth quarter from $71.91 million or $0.20 per share in the year-ago quarter. Analysts were looking for a wider loss.

The improvement in bottom-line performance reflects a sharp increase in revenues to $109.08 million, which surpassed analysts’ expectations. Net sales of Epidiolex, the company’s flagship product, came in at 104.5 million.

GW Pharma recorded operating cash flow of minus $123.5 million during the three-month period and ended the quarter with cash balance of $536.9 million.

Epidiolex Update

Epidiolex, the cannabidiol-based drug that was launched in the US early last year, later secured regulatory approval in Europe. Currently, the formulation is tested for additional indications in conditions like Tuberous Sclerosis Complex and Rett Syndrom.

“We expect 2020 to be an important year for our growing and developing product pipeline beyond Epidiolex as we build on our world leadership in cannabinoid science. We are focused on advancing nabiximols in the US in several indications and clinical programs with other potential products whilst continuing to bring Epidiolex to more patients in the US and Europe,” said CEO Justin Gover.

Outlook

Looking ahead, the company looks to broaden the prescriber base for Epidiolex this year, entering the long-term care segment and expanding payer coverage. It is on track to launch the drug in Europe in the first quarter, followed by launches in France and Italy.

Also see: GW Pharma Q3 2019 Earnings Call Transcript

Shares of GW Pharmaceuticals closed Tuesday’s regular session lower and dropped further during the extended trading session. The stock had a positive start to 2020 and gained 14% since the beginning of the year.

Also Read:  Cantel Medical Corp. (NYSE: CMD) Q4 2020 Earnings Call Transcript

Listen to publicly listed companies’ earnings conference calls along with the edited closed caption text

Most Popular

Infographic: How Cintas (CTAS) performed in Q1 2021

Cintas Corporation (NASDAQ: CTAS) reported first quarter 2021 earnings results today. Revenue was $1.75 billion, down 3.6% year-over-year.  Net income rose 19% to $300 million, or $2.78 per share, from

General Mills Q1 results top Wall Street expectations: Infographic

General Mills (NYSE: GIS) reported first-quarter 2020 financial results before the opening bell on Wednesday. The company reported a 9% increase in Q1 revenues to $4.36 billion, beating the Wall

JinkoSolar (JKS) Q2 Earnings: Key financials and quarterly highlights

JinkoSolar Holding Co., Ltd. (NYSE: JKS) reported second quarter 2020 earnings results today. Total revenues increased 22.2% year-over-year to RMB8.45 billion ($1.20 billion), exceeding the company’s guidance of $1.10 billion to $1.18 billion. The growth was

One thought on “GW Pharma (GWPH) Q4 loss narrows on strong sales; set to launch Epidiolex in Europe

Comments are closed.

Top